Genotropin GoQuick

Genotropin GoQuick

somatropin

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Recombinant somatropin
Indications/Uses
Replacement therapy in adults w/ pronounced growth hormone deficiency (GHD). Growth disturbance due to insufficient secretion of growth hormone or associated w/ Turner syndrome or chronic renal insufficiency in childn. Growth disturbance in short childn born small for gestational age (SGA) w/ birth wt &/or length <2 SD, who failed to show catch-up growth by ≥4 yr. Prader-Willi syndrome for improvement of growth & body composition.
Dosage/Direction for Use
SC GHD Adult Restart w/ 0.2-0.5 mg daily. Childn 0.025-0.035 mg/kg daily or 0.7-1 mg/m2 daily. Short childn born SGA 0.035 mg/kg daily or 1 mg/m2 daily until final height is reached. Chronic renal insufficiency 0.045-0.05 mg/kg daily or 1.4 mg/m2 daily. Onset GHD Adult Start w/ 0.15-0.3 mg daily. Patient who continue growth hormone therapy after childhood GHD Restart w/ 0.2-0.5 mg daily, adjust dose gradually according to requirements. Patient >60 yr 0.1-0.2 mg daily. Prader-Willi syndrome Childn 0.035 mg/kg daily or 1 mg/m2 daily. Max daily dose: 2.7 mg. Turner syndrome 0.045-0.05 mg/kg daily or 1.4 mg/m2 daily.
Contraindications
Hypersensitivity. Evidence of tumour activity. Patients w/ acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute resp failure. Childn w/ closed epiphyses.
Special Precautions
Discontinue use if papilloedema is confirmed. Not recommended to initiate treatment near onset of puberty in short childn born SGA. Leukemia; myositis; pancreatitis; acute critical illness; upper airway obstruction, sleep apnoea, resp infections. May reduce insulin sensitivity. Closely monitor patients w/ diabetes, glucose intolerance or additional risk factors for diabetes during therapy. Monitor thyroid function; signs of scoliosis. May unmask previously undiagnosed central hypoadrenalism. Relapse of GHD secondary to malignant disease treatment. Formation of Ab. Strict calorie-restricted diet & wt control in patients w/ Prader-Willi syndrome. Measure fasting insulin & blood glucose prior to & annually in SGA childn. Assess renal function prior to initiation of therapy. Discontinue treatment at renal transplantation. Not recommended during pregnancy & in women of childbearing potential not using contraception. Lactation. Elderly >80 yr. Examine childn limping during treatment.
Adverse Reactions
Inj site reaction, arthralgia, peripheral oedema. Paresthesia, benign intracranial HTN, carpal tunnel syndrome, myalgia, musculoskeletal stiffness.
Drug Interactions
Inhibited growth-promoting effects w/ glucocorticoids. Increased clearance of CYP450 3A4-metabolized compd eg, sex steroids, corticosteroids, anticonvulsants & ciclosporin.
ATC Classification
H01AC01 - somatropin ; Belongs to the class of somatropin and somatropin agonists. Used in anterior pituitary lobe hormone and analogue preparations.
Presentation/Packing
Form
Genotropin GoQuick inj 12 mg
Packing/Price
1's
Form
Genotropin GoQuick inj 5.3 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in